|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500112283 |
|
最近更新日期: Date of Last Refreshed on: |
2025-11-12 11:03:14 |
|
注册时间: Date of Registration: |
2025-11-12 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
急性缺血性脑卒中患者核心症状管理方案的构建与应用 |
|
Public title: |
Construction and application of a core symptom management program for acute ischemic stroke patients |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
急性缺血性脑卒中患者核心症状管理方案的构建与应用 |
|
Scientific title: |
Construction and application of a core symptom management program for acute ischemic stroke patients |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李晓梅 |
研究负责人: |
李娟 |
|
Applicant: |
Li Xiaomei |
Study leader: |
Li Juan |
|
申请注册联系人电话: Applicant telephone: |
+86 187 8503 1259 |
研究负责人电话:
Study leader's |
+86 138 8518 6730 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
1965320224@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
694807055@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
贵州省贵阳市中山东路83号 |
研究负责人通讯地址: |
贵州省贵阳市中山东路83号 |
|
Applicant address: |
83 Zhongshan East Road, Guiyang City, Guizhou Province |
Study leader's address: |
83 Zhongshan East Road, Guiyang City, Guizhou Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
贵州中医药大学/贵州省人民医院 |
||
|
Applicant's institution: |
Guizhou University of Traditional Chinese Medicine/Guizhou Provincial People's Hospital |
||
|
研究负责人所在单位: |
贵州省人民医院 |
||
|
Affiliation of the Leader: |
Guizhou Provincial People's Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦审(科研)2025-224号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
贵州省人民医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Guizhou Provincial People's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-11-06 00:00:00 | ||
|
伦理委员会联系人: |
邓蕊 |
||
|
Contact Name of the ethic committee: |
Deng Rui |
||
|
伦理委员会联系地址: |
贵州省贵阳市中山东路83号 |
||
|
Contact Address of the ethic committee: |
83 Zhongshan East Road, Guiyang City, Guizhou Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 851 8560 0570 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
贵州省人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Guizhou Provincial People's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
贵州省贵阳市中山东路83号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
83 Zhongshan East Road, Guiyang City, Guizhou Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹经费 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-financing |
||||||||||||||||||||||
|
研究疾病: |
卒中 |
||||||||||||||||||||||
|
Target disease: |
stroke |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
1.明确急性缺血性脑卒中患者核心症状; 2.构建急性缺血性脑卒中患者核心症状管理方案; 3.验证构建的核心症状管理方案在急性缺血性脑卒中患者中的应用效果,初步评价该方案在临床应用中的可行性及有效性。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. Identify the core symptoms of patients with acute ischaemic stroke; 2. Develop a core symptom management protocol for patients with acute ischaemic stroke; 3. Validate the efficacy of the developed core symptom management protocol in acute ischaemic stroke patients, and conduct a preliminary assessment of its feasibility and effectiveness in clinical practice. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄>=18岁; 2.依据 2019 年修订的《中国各类主要脑血管病诊断要点》中脑卒中诊断要点,并由临床医生经病史、体格检查、CT/MRI 检查确诊为急性缺血性脑卒中患者; 3.发病2周内;4.经治疗后生命体征平稳,意识状态清楚;5.自愿参与本研究并配合问卷调查,签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
1.aged >=18 years; 2.patients diagnosed with acute ischemic stroke based on the diagnostic points of stroke in the revised Diagnostic Points for All Types of Major Cerebrovascular Diseases in China in 2019 and diagnosed by a clinician by history, physical examination, and CT/MRI examination; 3.within 2 weeks of onset of the disease; 4. stable vital signs and a clear state of consciousness after treatment; and 5. voluntarily participating in this study and cooperating with the questionnaire survey and sign the informed consent form. |
||||||||||||||||||||||
|
排除标准: |
1.存在严重认知障碍及精神疾病史的患者; 2.合并严重心、肝、肾功能不全、呼吸衰竭及恶性肿瘤等慢性病或脏器功能严重异常者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.patients with a history of severe cognitive impairment and psychiatric disorders; 2.patients with comorbidities such as severe cardiac, hepatic, and renal insufficiency, respiratory failure, and malignant tumors, and other chronic diseases or severe abnormalities of organ function. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-11-17 00:00:00至 To 2027-03-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-11-17 00:00:00 至 To 2026-11-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
研究者采用随机数字表法获取不重复的随机数字,偶数为观察组,奇数为对照组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The researchers used the random number table method to obtain non-repeating random numbers, even numbers were the observation group, and odd numbers were the control group. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
对患者采取单盲法,即不告知患者本人是处于试验组还是对照组。 |
|
Blinding: |
The patients were single-blinded, they were not told whether they were in the test or control group. |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究公开发表后邮件联系研究负责人合理取得。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
After the publication of the study, contact the research director by email for reasonable access. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF;EDC |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF;EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |